AN2 Therapeutics Inc (ANTX)
2.265
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
2.265
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Research and Development Expense (Annual): 54.87M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 54.87M |
| December 31, 2022 | 29.51M |
| Date | Value |
|---|---|
| December 31, 2021 | 16.91M |
| December 31, 2020 | 6.019M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
6.019M
Minimum
2020
54.87M
Maximum
2023
26.83M
Average
23.21M
Median
Research and Development Expense (Annual) Benchmarks
| Revance Therapeutics Inc | 79.41M |
| Viking Therapeutics Inc | 63.81M |
| VYNE Therapeutics Inc | 16.31M |
| Aquestive Therapeutics Inc | 13.10M |
| Humacyte Inc | 76.55M |